Immunohistochemical analysis validated the concurrent downregulation and strong positive correlation of FAT2 and CLDN19 in clinical specimens.<h4>Conclusions</h4>FAT2 functions as a tumor suppressor in breast cancer by inhibiting migration, invasion, and EMT through transcriptional upregulation of CLDN19. This evidence concerns the gene CLDN19 and neoplasm.